Utility of 18F-fluoroestradiol PET / CT in the differential diagnosis of estrogen receptor-positive breast cancer: case series

Cover Page

Cite item

Full Text

Abstract

Breast cancer is one of the most common female cancers and the leading cause of cancer death in women. The method of positron emission tomography, combined with computed tomography, makes it possible to assess not only anatomical and structural, but also metabolic changes in tumor tissue. The increased accumulation of 18F-fluoroestradiol in the pathological focus correlates with the estrogen receptor-positive status of the tumor, which is confirmed by tissue immunohistochemistry studies. The receptor status of a tumor formation fundamentally affects the choice of therapeutic tactics. The presented clinical examples demonstrate the capabilities of positron emission tomography, combined with computed tomography, with 18F-fluoroestradiol in the diagnosis of the estrogen receptor-positive tumor lesions.

About the authors

A. V. Parnas

Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia

Author for correspondence.
Email: alexandrparnas@gmail.com
ORCID iD: 0000-0002-2963-4176

Build. 1, 2 / 1 Barrikadnaya St., Moscow 125993, Russia

Russian Federation

A. I. Pronin

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

ORCID iD: 0000-0003-1632-351X

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

V. S. Ilyakov

Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia

ORCID iD: 0000-0002-5375-2498

Build. 1, 2 / 1 Barrikadnaya St., Moscow 125993, Russia

Russian Federation

N. A. Meshcheryakova

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

ORCID iD: 0000-0003-0770-3406

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

Z. Kh. Kamolova

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

ORCID iD: 0000-0002-4376-3978

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

D. I. Nevzorov

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

ORCID iD: 0000-0003-2969-0191

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

References

  1. Malignant tumors in Russia in 2017 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Radiological Center, Ministry of Health of Russia, 2018. 250 p. (In Russ.).
  2. Waks A.G., Winer E.P. Breast cancer treatment: A review. JAMA 2019;321(3): 288–300. doi: 10.1001/jama.2018.19323.
  3. Hospers G.A., Helmond F.A., de Vries E.G. et al. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 2008;14:3020–32. doi: 10.2174/138161208786404362.
  4. Bonacho T., Rodrigues F., Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem 2019;1–21. doi: 10.1080/10520295.2019.1651901.
  5. Seenu V., Sharma A., Kumar R. et al. Evaluation of estrogen expression of breast cancer using 18F-FES PET CT-A novel technique. World J Nucl Med 2020;19:233–9.
  6. Dehdashti F., Mortimer J.E., Siegel B.A. et al. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG‐PET and in vitro receptor assays. J Nucl Med 1995;36:1766–74.
  7. Gemignani M.L., Patil S., Seshan V.E. et al. Feasibility and predictability of perioperative pet and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med 2013;54:1697–1702. doi: 10.2967/jnumed.112.113373.
  8. Kurland B.F., Peterson L.M., Lee J.H. et al. Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res 2017;23:407–15. doi: 10.1158/1078-0432.CCR-16-0362.
  9. Liao G.J., Clark A.S., Schubert E.K. et al. 18F‐fluoroestradiol PET: Current status and potential future clinical applications. J Nucl Med 2016;57:1269–75. doi: 10.2967/jnumed.116.175596.
  10. Peterson L., Manohar P., Wu V. et al. 18F‑Fluoroestradiol (FES) and 18F‑Fluorodeoxyglucose (FDG) PET imaging in male breast cancer. J Nucl Med 2018;59(Suppl 1):54. doi: 10.1158/1078-0432.CCR-16-0362.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.